Sign in

AHG on Nasdaq

Akso Health Group

Akso Health Group is a business services company in the Cayman Islands, listed on Nasdaq (AHG).1 It is headquartered in Qingdao Pilot Free Trade Zone, China.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$13.8MRevenue, fiscal 20262
-$18.7MNet income, fiscal 20262

Compare with Swvl, MOGU Inc. or Ryde Group Ltd, or pick any stock.

  • TickerAHG on Nasdaq1
  • IndustryServices-Business Services, NEC1
  • HeadquartersQingdao Pilot Free Trade Zone, China1
  • Incorporated inCayman Islands3
  • Business addressRm 8201-4-4(A) 2Nd Floor Qiantongyua Bld, No. 44 Moscow Rd Qianwan Bonded Port Are, Qingdao Pilot Free Trade Zone, F4 00003
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

Hexin Yongheng, which to this date remains Hexindai HK’s wholly-owned subsidiary in China, in August 2016.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-0.1%Gross margin2
-149.7%Operating margin2
-135.0%Net margin2
-6.4%Revenue growth, 20262
-10.3%Return on equity2
-$12.8MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Revenue brought in 50% of the revenue Akso Health Group broke down this way in fiscal 2026.

  1. Revenue$13.8M250%down 6% from 2025
  2. Revenue From Marketing Promotion Service$13.8M250%down 4% from 2025
Products and services by year
Products and services202420252026
Revenue$2.4M$14.8M$13.8M
Revenue From Marketing Promotion Service$14.4M$13.8M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue70¢$13.8M
  • Selling, general and admin20¢$4.0M
  • Income tax10¢$2.0M

Out of $13.8M in revenue.2 The company lost money this year.

Financial statements

Revenue5672$13.8M in 2026+274% since 2019
0$5.0M$10.0M$15.0M2019: $3.7M$3.7M20192020: $6.9M$6.9M2020+87%2021: $1.8M$1.8M2021−75%2022: $6.3M$6.3M2022+260%2023: $13.2M$13.2M2023+109%2024: $2.4M$2.4M2024−82%2025: $14.8M$14.8M2025+512%2026: $13.8M$13.8M2026−6%
Gross profit6872-$11.3K in 2026
-$2.0M0$2.0M$4.0M$6.0M$8.0M2020: $6.9M$6.9M20202021: $1.8M$1.8M2021−75%2022: $605.1K$605.1K2022−66%2023: $1.3M$1.3M2023+110%2024: $122.1K$122.1K2024−90%2025: -$281.5K-$281.5K20252026: -$11.3K-$11.3K2026−96%
Operating income569872-$20.7M in 2026+188% since 2019
-$200.0M-$150.0M-$100.0M-$50.0M02019: -$7.2M-$7.2M20192020: -$48.1M-$48.1M2020+569%2021: -$4.2M-$4.2M2021−91%2022: -$3.3M-$3.3M2022−23%2023: -$14.3M-$14.3M2023+338%2024: -$8.6M-$8.6M2024−39%2025: -$166.3M-$166.3M2025+1825%2026: -$20.7M-$20.7M2026−88%
Net income569872-$18.7M in 2026
-$150.0M-$100.0M-$50.0M0$50.0M2019: $5.5M$5.5M20192020: -$71.2M-$71.2M20202021: -$34.8M-$34.8M2021−51%2022: -$16.9M-$16.9M2022−52%2023: -$1.4M-$1.4M2023−92%2024: -$9.5M-$9.5M2024+596%2025: -$135.0M-$135.0M2025+1327%2026: -$18.7M-$18.7M2026−86%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2026-03-312025-03-312024-03-31
Net Revenues$13.8M$14.8M$2.4M
Cost of revenue$13.8M$15.1M$2.3M
Gross Profit-$11.3K-$281.5K$122.1K
Sales and marketing$168.4K
General and administrative$4.0M$3.6M$8.6M
Impairment of goodwill and intangible assets$16.7M$162.4M
Total Operating Expenses$20.7M$166.0M$8.8M
LOSS FROM CONTINUING OPERATIONS-$20.7M-$166.3M-$8.6M
Other income$344$47.1K$252.4K
Other expense-$4.7K-$13.0K-$114.2K
Exchange gain (loss)$272-$26-$592.0K
Total Other (Expense) Income, net-$4.1K$34.1K-$453.8K
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES-$20.7M-$166.3M-$9.1M
(BENEFIT) PROVISON FOR INCOME TAXES-$2.0M-$30.8M$25.0K
NET LOSS FROM CONTINUING OPERATIONS-$18.7M-$135.5M-$9.1M
Net loss from discontinued operations, net of income taxes-$3.9K
Loss from disposal of discontinued operations, net of income taxes-$395.9K
Total loss from discontinued operations-$399.8K
Less: net loss attributable to non-controlling interest-$44.6K-$491.8K-$57.8K
NET LOSS ATTRIBUTABLE TO AKSOS SHAREHOLDERS-$18.7M-$135.0M-$9.5M
NET LOSS-$18.7M-$135.5M-$9.5M
Foreign currency translation adjustment$487.4K$312.1K-$238.6K
COMPREHENSIVE LOSS-$18.2M-$135.2M-$9.8M
Less: comprehensive loss attributable to non-controlling interest-$44.2K-$494.9K-$57.4K
COMPREHENSIVE LOSS ATTRIBUTABLE TO AKSOS SHAREHOLDERS-$18.2M-$134.7M-$9.7M
Basic (in Dollars per share)$0$0$0
Diluted (in Dollars per share)$0$0$0
Basic (in Dollars per share)$0.01$0.16$0.07
Diluted (in Dollars per share)$0.01$0.16$0.07
Basic (in Shares)2.2B shares855.3M shares141.5M shares
Diluted (in Shares)2.2B shares855.3M shares141.5M shares

Compare Akso Health Group with another company

What it owns

What Akso Health Group reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$8.4K2 Mar 31, 2026$1.6K2 Mar 31, 2025+418.2%
Property and equipment, net$12.0K2 Mar 31, 2026$16.1K2 Mar 31, 2025−25.6%
Operating-lease assets (leased space)$16.9K2 Mar 31, 2026$98.4K2 Mar 31, 2025−82.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$170.6K2 Mar 31, 2026$176.2M2 Mar 31, 2025−99.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$10.8M2 Mar 31, 2025$52.1M7 Apr 15, 2024−79.2%
Intangible assets, net (excluding goodwill)$58.3K2 Mar 31, 2026$7.9M2 Mar 31, 2025−99.3%
Finite-lived intangibles, gross$10.5M2 Mar 31, 2026$130.5M2 Mar 31, 2025−91.9%
Accumulated amortization$4.7M2 Mar 31, 2026$2.1M2 Mar 31, 2025+119.2%
Finite-lived intangibles, net$58.3K2 Mar 31, 2026$7.9M7 Mar 31, 2025−99.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$200.1K2 Mar 31, 2026$190.2K2 Mar 31, 2025+5.2%
Finished goods$200.1K2 Mar 31, 2026$190.2K2 Mar 31, 2025+5.2%

Leadership

Who has led Akso Health Group, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (4)

Former names

  • Xiaobai Maimai Inc.Nov 24, 2020 to Dec 17, 20213
  • Hexindai Inc.Apr 7, 2017 to Dec 21, 20203

Filings

63 filings to the SEC since October 2021: 5 annual reports, 6 insider forms, 52 other. The latest 20:

  1. Jul 23, 202620-F ANNUAL REPORT EDGAR
  2. May 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Apr 6, 20263 PRIMARY DOCUMENT EDGAR
  4. Mar 30, 20263 PRIMARY DOCUMENT EDGAR
  5. Mar 27, 20263 PRIMARY DOCUMENT EDGAR
  6. Mar 23, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Mar 18, 20263 PRIMARY DOCUMENT EDGAR
  8. Mar 18, 20263 PRIMARY DOCUMENT EDGAR
  9. Mar 18, 20263 PRIMARY DOCUMENT EDGAR
  10. Feb 10, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  11. Aug 14, 202520-F ANNUAL REPORT EDGAR
  12. Jul 31, 2025NT 20-F EDGAR
  13. Jun 6, 2025EFFECT EDGAR
  14. Jun 5, 2025CORRESP EDGAR
  15. May 22, 2025CORRESP EDGAR
  16. May 22, 2025F-3/A AMENDMENT NO. 3 TO FORM F-3 EDGAR
  17. May 1, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Mar 28, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Jan 30, 2025UPLOAD EDGAR
  20. Jan 6, 2025F-3/A AMENDMENT NO. 2 TO FORM F-3 EDGAR

The 63 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Renaissance Technologies LLC70,943$105.7K0.0%−27,455
Northern Trust Corp51,403$76.6K0.0%+4,528
Citadel Advisors LLC46,026$68.6K0.0%New
SmartHarvest Portfolios, LLC44,755$66.7K0.0%+9,326
Jane Street Group, LLC41,360$61.6K0.0%+10,123
Geode Capital Management, LLC14,973$22.3K0.0%No change
BlackRock, Inc.10,064$15.0K0.0%+10,027
UBS Group AG963$1.4K0.0%New
Morgan Stanley739$1.1K0.0%New
Huntington National Bank419$6240.0%New
Caitong International Asset Management Co., Ltd2$30.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Akso Health Group is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAkso Health Group1
  • CIK0001702318
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inCayman Islands4
  • Fiscal year endsMarch 311
  • Industry code (SIC)7389 Services-Business Services, NEC1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business addressRm 8201-4-4(A) 2Nd Floor Qiantongyua Bld, No. 44 Moscow Rd Qianwan Bonded Port Are, Qingdao Pilot Free Trade Zone, F4 00001
  • Phone86 152 1005 49191
  • Shares outstanding2,562,131,730 Common Class A shares; 7,980,800 Common Class B shares as of Mar 31, 20264
  • AuditorCHI-LLTC, Perak, Malaysia PCAOB ID 7320; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceApr 7, 20171
  • Filings195 in all: 6-K (96), CORRESP (17), UPLOAD (16), 20-F (9), 3 (6), DRSLTR (6), SC 13G/A (6), DRS/A (5)1
    All 27 form types

    EFFECT (5), F-3/A (5), F-3 (3), NT 20-F (3), 424B3 (2), F-6 POS (2), SC 13G (2), 144 (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERTNAS (1), DRS (1), F-1 (1), F-1/A (1), F-6 (1), RW (1), S-8 (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) Jul 23, 2026

Securities registered for trading

ClassSymbolExchange
American depositary shares (one American depositary share representing three Class A ordinary shares, par value US$0.0001 per share)AHGNasdaq
Class A ordinary shares, par value US$0.0001 per shareNasdaq

From the cover page of the 20-F filed Jul 23, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14